Package Leaflet: Information for the User
Narine Repetabs5mg/120mg prolonged-release tablets
loratadine/pseudoephedrine sulfate
Read all of this leaflet carefully before you start takingthis medicine because it contains important information for you.
Contents of the pack and other information
What is Narine Repetabs
Narine Repetabs tablets contain a combination of two medicines, an antihistamine (loratadine) and a decongestant (pseudoephedrine).
How Narine Repetabs works
Narine Repetabs helps to reduce the symptoms of allergy or common cold by blocking the effects of a substance called "histamine", which the body produces when it is allergic to something. The decongestants help to clear nasal congestion.
When to use Narine Repetabs
Narine Repetabs tablets relieve the symptoms associated with seasonal allergic rhinitis (hay fever), such as sneezing, runny or itchy nose or eyes when accompanied by nasal congestion in adults and adolescents from 12 years of age.
Do not take Narine Repetabs
Due to its pseudoephedrine content, do not take Narine Repetabs
Warnings and precautions
Certain diseases may make you unusually sensitive to the pseudoephedrine decongestant contained in this medicine.
Consult your doctor or pharmacist before starting to take Narine Repetabs:
Tell your doctor if you notice or are diagnosed with any of the following:
One of the active ingredients of Narine Repetabs, pseudoephedrine sulfate, can cause dependence and large amounts of pseudoephedrine sulfate can be toxic.
If you develop a generalized febrile erythema associated with pustules, stop taking Narine Repetabs and contact your doctor or seek immediate medical attention. See section 4.
Sudden abdominal pain or rectal bleeding may occur with the use of Narine Repetabs, due to inflammation of the colon (ischemic colitis). If these gastrointestinal symptoms appear, stop taking Narine Repetabs and contact your doctor or seek immediate medical attention. See section 4.
A reduction in blood flow to the optic nerve may occur with Narine Repetabs. If you experience sudden loss of vision, stop taking Narine Repetabs and contact your doctor or seek immediate medical attention. See section 4.
There have been reports of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) after the use of medications containing pseudoephedrine. PRES and RCVS are rare diseases that can involve a reduction in blood flow to the brain. Stop using Narine Repetabs immediately and seek immediate medical attention if you experience symptoms that may be signs of PRES or RCVS (to learn about the symptoms, see section 4 "Possible side effects").
Children
Do not give this medicine to children under 12 years of age.
Taking Narine Repetabs withother medicines
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including those obtained without a prescription.
Taking Narine Repetabs with alcohol
It has not been shown that Narine Repetabs enhances the effects of alcohol.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
Pregnancy
Do not take Narine Repetabs if you are pregnant.
Breastfeeding
Do not take Narine Repetabs if you are breastfeeding.
Loratadine and pseudoephedrine are excreted in breast milk. A decrease in milk production has been reported in breastfeeding mothers with the use of pseudoephedrine, a component of Narine Repetabs.
Driving and using machines
At the recommended dose, it is not expected that Narine Repetabs will cause drowsiness or decreased alertness. However, very rarely, some people may experience drowsiness, which may affect their ability to drive or use machines.
Narine Repetabs contains lactose and sucrose
Narine Repetabs contains lactose and sucrose. If your doctor has told you that you have an intolerance to certain sugars, consult with them before taking this medicine.
Laboratory tests:Athletes are informed that this medicine contains a component that may result in a positive doping control test.
Follow exactly the administration instructions of this medicine indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
How to take
Adults and adolescents aged 12years and over:
The recommended dose is one Narine Repetabs prolonged-release tablet twicea day with a glass of water, regardless of meals.
This medicine is taken orally. Swallow the tablet whole; do not crush, break, or chew the tablet before swallowing.
Do not take more Narine Repetabs tablets than recommended in this leaflet, or more frequently than recommended.
Do not take this medicine for more than 10 consecutive days unless your doctor tells you to do so.
If you take more Narine Repetabs than you should
If you take more Narine Repetabs than you should, consult your doctor or pharmacist immediately. Drowsiness, palpitations, and headache have been reported with loratadine overdose, a component of Narine Repetabs. Convulsions, palpitations, nausea, and nervousness have been reported with pseudoephedrine overdose, a component of Narine Repetabs.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service; Telephone 91 562 04 20 indicating the medicine and the amount ingested.
If you forget to take Narine Repetabs
If you have any other questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. Contact your doctor or pharmacist immediately if you experience a side effect that does not go away, is bothersome, or you think is important.
Frequency not known: cannot be estimated from the available data
Stop using Narine Repetabs immediately and seek urgent medical attention if you experience symptoms that may be signs of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS). These include:
The side effects that occur very frequently with Narine Repetabs (may affect more than 1 in 10 patients) include: insomnia.
The side effects that occur frequently with Narine Repetabs (may affect up to 1 in 10 patients) include: drowsiness, nervousness, somnolence, depression, agitation, anorexia, dizziness, dry mouth, rapid heartbeats, sore throat, nasal mucosa inflammation, constipation, nausea, headache, and fatigue.
The side effects that occur infrequently (may affect up to 1 in 100 patients) include: confusion, tremor, increased sweating, hot flashes, altered taste, abnormal eye tearing, ringing in the ears, irregular heartbeat, nasal bleeding, and frequent or abnormal urination and itching.
During the marketing of Narine Repetabs, the following side effects have occurred with a very rarefrequency (may affect up to 1 in 10,000 patients): severe allergic reaction including rash, urticaria, and swelling of the face, vertigo, seizures, abnormal heart rhythms, increased blood pressure, cough, bronchial constriction, liver problems, difficulty urinating, and hair loss.
Other adverse reactions that were only reported for loratadine in clinical trials and during the post-marketing period include increased appetite, rash, and stomach discomfort.
The frequency of the following side effects is not known:
Stop taking Narine Repetabs if these symptoms appear and contact your doctor or seek immediate medical attention.
Reporting of side effects:
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the Spanish Pharmacovigilance System for Human Use Medicines: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
The expiry date is the last day of the month stated.
Composition of Narine Repetabs
Appearance of the product and pack size
Narine Repetabs 5 mg/120 mg prolonged-release tablets are presented in blisters in pack sizes of 1, 7, 10, 14, 20, 28, 30, 50, and 100 tablets.
Not all pack sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder
Bayer Hispania, S.L.
Av. Baix Llobregat, 3-5
08970 Sant Joan Despí (Barcelona)
Spain
Manufacturer
SAG Manufacturing, S.L.U.
Carretera N-1, Km 36
28750, San Agustín de Guadalix (Madrid)
Spain
This medicine is authorized in the Member States of the European Economic Area under the following names:
Austria: Clarinase
Belgium: Clarinase Repetabs
Spain: Narine Repetabs 5mg/120mg prolonged-release tablets
Greece: Clarityne-D 120/5
Portugal: Claridon
Date of last revision of this leaflet: 10/2024
Other sources of information
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/